Navigation Links
XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
Date:5/28/2008

We are excited to have Larry join our Board of Directors. Through his many years of experience in public accounting, Larry is well-versed in matters related to SEC and Sarbanes-Oxley compliance. We believe that his skills provide a valuable addition to XTL's Board, as we prepare for the next stage of the company's growth following what we hope will be a successful completion of our Phase 2b study of Bicifadine in Q4 2008."

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for our clinical compound for neuropathic pain, Bicifadine, growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially is our ability to complete in a timely and cost effective manner clinical trials on Bicifadine, which
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
4. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
7. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
8. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
9. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
10. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
11. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Chelating Agents Market ... About Chelating Agent A chelating agent is ... with metal ions, thereby forming a metal-ion complex. ... have on chemical processes, formulations, and the environment ...
(Date:8/27/2014)... , Aug. 27, 2014  Lisa Kulik saw ... this July 4 holiday, thanks to a groundbreaking retinal ... an internationally renowned clinician-researcher at the University of Southern ... 55-year-old Peoria, Ariz. resident who ... its victims of sight. On June 2, she became ...
(Date:8/27/2014)... Belmont, Mass. (PRWEB) August 27, 2014 ... of top technology vendors,” said Ven Thangaraj, CEO of ... imaging solutions that are taking the imaging corelab market ... trial sponsors, corelabs and research organizations to efficiently and ... and prepare the data to be analyzed and read ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... 7 Medicsight PLC, a subsidiary,of MGT Capital ... industry leader in the,development of Computer-Aided Detection (CAD) ... received approval from the Brazilian regulatory,agency, Agencia Nacional ... David Sumner, Chief Executive of Medicsight, commented: "This ...
... DENVER, Aug. 7 Quest Product Development, ... a $1,000,000 Small Business,Technology Transfer grant by ... the development of a next-generation endoscope. MicroFlex,technology, ... alloys and,micro-actuators that allow active control over ...
... AutoImmune Inc. (OTC,Pink Sheets: AIMM) today reported a net ... the three months ended June 30, 2008, compared with,a net ... diluted, for the,three months ended June 30, 2007. For the ... or $0.01 per share basic and diluted, compared,with net loss ...
Cached Biology Technology:Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 2Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 3NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3
(Date:8/28/2014)... Minn. A Mayo Clinic researcher and his collaborators ... up and enhance the process of re-engineering cells for ... uses network biology methods to aid stem cell engineering. ... engineering are described in two back-to-back papers in the ... a broad range of uses for all types of ...
(Date:8/28/2014)... identified the developmental on-off switch for Streptomyces , ... two-thirds of the world,s naturally derived antibiotic medicines. ... it is possible to manipulate this switch to make ... appearing August 28 in Cell , found that ... and a larger protein called BldD ultimately controls whether ...
(Date:8/28/2014)... good examples of complex systems. Their infrastructure equipment ... for cooling, transport to supply fuel, and ICT ... the network chain is interconnected with a wider ... team of UK-based scientists has studied various aspects ... have been published in EPJ B by Gaihua ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Inter-dependent networks stress test 2
... computer-based text-searching tool developed by UT Southwestern Medical Center ... in a database for similarities, providing a more efficient ... offering scientific journal editors a new tool to thwart ... efficient at flagging publications that are highly similar, said ...
... automated sensors may soon help NOAA scientists better predict ... ice will melt, and whether soggy Pacific storms will ... of NOAAs Unmanned Aircraft Systems program. NOAA recently ... use of the crewless vehicles for wide-ranging research designed ...
... of this message: , About the Ocean Sciences ... Book Hotel Rooms by 4 February 2008 Abstracts and ... Ocean Sciences Meeting , This years meeting will offer ... and Earths water wherever it is found, from mountain ...
Cached Biology News:Computer-based tool aids research, helps thwart questionable publication practices 2Computer-based tool aids research, helps thwart questionable publication practices 3NOAA invests $3 million for unmanned aircraft system testing 2Media advisory -- 2008 Ocean Sciences Meeting 2Media advisory -- 2008 Ocean Sciences Meeting 3Media advisory -- 2008 Ocean Sciences Meeting 4
... Reagent B - Permeabilisation medium LEUCOPERM ... suspension with Reagent A and then permeabilising ... gives antibodies access to intracellular structures and ... cells intact. Specific formulations reduce background staining ...
... Rabbit polyclonal to JNK1 (phospho T183 + Y185) ... internal domain containing phosphorylated T183/Y185. Reactivity / ... Not yet tested in other species. Background ... including the ERK, JNK, and p38 kinases. The ...
... Dako Target Retrieval Solution, pH 9 ... Tris/EDTA buffer, pH 9, intended for heat-induced ... It is well-suited for use on formalin-fixed, ... Compared with 0.01 mol/L citrate buffer, pH ...
... has been designed to provide a thin film-like barrier ... a slide. This barrier creates the proper surface ... area on the slide. PAP Pen contains a ... It can be removed, if desired, by xylene ...
Biology Products: